IMMUSE

IMMUSE Therapeutics is a South Korean biotechnology company specializing in the development of innovative immuno-oncology therapies. Founded in 2021, the company focuses on small molecule medicines and next-generation antibody-drug conjugates (ADCs) that simultaneously target tumor cells and immune cells within the tumor microenvironment. Their lead program, IMT-101, is designed to overcome resistance to PARP inhibitors in solid tumors like ovarian and triple-negative breast cancer. IMMUSE utilizes a proprietary platform for phenotype screening and target identification to reinvigorate exhausted T-cells and enhance drug sensitivity. The company is a member of JLABS@Shanghai and has established a U.S. subsidiary, IMMUSE Pharmaceuticals, to support global clinical development.